A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

Dave Riley, from East Lancashire Prostate Cancer Support, said men over 50 can get tested annually, but "you can get checked ...

Statistics, and the standard deviation of our tests, mean that if you order a complete metabolic profile, a lipid panel, a ...

AS the air gets crisp, and more people in the office sniffle, thoughts inevitably turn to the immune system. Everyone is ...

Disease activity and multimorbidity among patients in the US with PsA varied based on geographic region, socioeconomic deprivation, race, and gender.

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

On-treatment PSA and disease burden should be considered together for prognostication. Achieving PSA ≤0.2 ng/mL within 6–12 weeks strongly predicts favorable long-term survival. Metastatic volume and ...

When it comes to protecting your heart, preventative testing is key. Keeping track of important metrics like blood pressure ...

SYMPLIFY, a prospective observational study, is the first large-scale evaluation of a multi-cancer early detection (MCED) test in individuals who presented with symptoms to primar ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Aurelius Omlin discussing optimized use of immunotherapy and targeted ...